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Interleukin-13-mediated colitis in the absence of IL-4Rα signalling 
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Sufficient evidence points to interleukin (IL)-13 as an important pathological factor in 
ulcerative colitis and raises hopes to a promising new treatment strategy, [1-3]. However, 
the outcome of two recent clinical trials, both published in Gut 2015 suggest otherwise, 
[4, 5]. A commentary published in the same issue, described these results as crushing the 
enthusiasm for anti-IL-13 treatment in ulcerative colitis, [6]. In this letter we show 
evidence that the disease outcome is determined by the type of signalling pathway 
utilized by IL-13 in mice. Therefore we suggest that directly blocking IL-13 remains a 
potential treatment strategy for a subset of ulcerative colitis patients that have elevated 
tissue IL-13 production.  
In the first clinical study using Anrukinzumab treatment, which targets the IL-4 receptor-
alpha (IL-4Rα) and not IL-13 directly, had no effect on improving the clinical response 
or remission rates of ulcerative colitis patients, [4].  In contrast, although patients treated 
with Tralokinumab, which blocks IL-13 directly, showed no improved clinical response 
rate, there was a significantly improved clinical remission rate and partial Mayo score at 
week 4 in these patients [5]. Here it was suggested that the ability of patients to respond 
to Tralokinumab depends on baseline levels of colonic mucosal IL-13 and that targeting 
a sub-group of patients with high levels of mucosal IL-13 may prove to be beneficial in 
these patients. Highlighting the mode of action of the therapies above, IL-4 and IL-13 
both signal through the IL-4Rα. This receptor is part of the type I (IL-4Rα/γc) and type II 
(IL-4Rα/IL-13α1) receptor complexes. While Anrukinzumab only blocks signalling of 
IL-13 through IL-4Rα, Tralokinumab blocks IL-13 itself, and would therefore prevent 
IL-13 from binding any other potential receptors.  
Using a mouse model of acute oxazolone-induced colitis [7, 8], we confirmed that IL-13-
deficient mice are protected from developing colitis (Table 1, see IL-13
-/-
,
 
Supplementary 
figure 1 and Supplementary figure 2).  
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Table 1: Disease activity in oxazolone treated gene-deficient or transgenic BALB/c mice. 
Groups Body 
weight a 
Distress 
Scoreb 
Colon 
length (cm) 
Colitis 
Score c 
Previously  
published 
BALB/c etoh 98.19±1.6 3.33±0.2 8.23±0.5 2.78±0.5 BALB/c [2] 
BALB/c oxa 91.66±1.8 * 9.38±0.9 *** 6.81±0.4 * 8.33±0.8*** BALB/c [2] 
BALB/c IL-4-/- 89.85±1.4 ** 9.34±1.2 ** 7.84±0.6 6.78±1.3* SJL/J anti-IL-4 [9] 
BALB/c IL-13-/- 98.74±1.5 # 5.50±0.5 # 9.53±0.6 5.50±0.6 # BALB/c IL-13-/-[2]  
C57Bl/10 anti-IL-13 [7] 
BALB/c IL-13 trans 88.50±1.2 # 12.33±1.2 ## 6.50±0.6 ** 12.00±0.5##  
BALB/c IL-4Rα-/-/IL-4-/- 87.21±2.2 ** 9.00±1.4 * 7.47±0.1 * 9.57±0.5***  
* = p <0.05, ** = p <0.01 and *** = p <0.001 vs BALB/c etoh control. 
#
 = p <0.05 and 
##
 = p <0.01 BALB/c oxa vs. genetically modified mice. 
a
 Body weight is shown as percentage starting weight 2 days post-challenge. 
b
 Distress is scored according to appearance, clinical signs, natural and provoked behaviour. 
c 
Colitis score out of 15 (Supplementary methods). 
In striking contrast, mice deficient for IL-4Rα, [10] are highly susceptible to disease 
onset and develop an exacerbated pathology compared to BALB/c wild-type control 
mice (Figure 1A-D, Supplementary methods). Rapid onset colitis was marked by weight 
loss and an increased distress score. Macroscopic examination revealed severe colitis 
limited to the distal half of the colon, with inflammation-associated colon shortening. 
Microscopic examination showed superficial inflammation scored according to the 
presence of mononuclear cells, oedema, infiltration of granulocytes, epithelial layer 
disruption and loss of mucus production. The IL-13-driven pathology can be reverted to 
protection in IL-4Rα/IL-13-double deficient mice (Figure 1A-D). Hence, the protection 
in these mice and the detectable level of IL-13 in IL-4Rα-deficient mice suggests a 
potential role of IL-13 signalling in mediating colitis, independently of the IL-4Rα.  
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Although further investigation is required to confirm a mechanism of the IL-4Rα-
independent signalling pathway of IL-13, our results are important to consider when 
designing new therapeutic strategies against T helper type 2-mediated inflammation. 
This data also suggests that attempts to neutralize IL-4Rα may indeed have a detrimental 
outcome on disease. Furthermore, results from our previous work in an ovalbumin-
induced dermatitis model suggest that this mechanism may not be limited to ulcerative 
colitis [11]. In dermatitis, the complete protection of IL-4Rα/IL-13-double deficient but 
not IL-4Rα mice was associated with a decrease in Extracellular signal-regulated kinases 
(ERK) phosphorylation of the Mitogen-activated protein kinases (MAPK) signal 
transduction pathway. This alludes to the possible involvement of IL-13 signalling 
through the IL-13Rα2, or theoretically an unknown IL-13 receptor. In summary, we 
conclude that IL-13 signalling is able to drive colitis in the absence of IL-4Rα and 
suggest that anti-IL-13 treatment but not anti-IL-4Rα treatment strategies could still be 
beneficial in a subset of ulcerative colitis patients with increased IL-13. 
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FIGURE LEGEND 
Figure 1 
Deletion of IL-4Rα exacerbates oxazolone-induced colitis which is rescued in the 
absence of IL-13 
(A) Body weight (day6) and distress score (day2). (B) Macroscopic appearance and 
colon length. (C) PAS-stained distal colon and colitis score. (D) Mesenteric lymph node 
IL-13 production. Data represents 2-3 individual experiments (n=4-10 mice) and 
*=p<0.05, **=p<0.01 and ***=p<0.001, IL-4Rα-/- oxa vs. IL-4Rα-/-/IL-13-/- oxa mice.  
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1 
IL-4/IL-13 mediates oxazolone-induced colitis in BALB/c mice 
(A) Body weight (day7) and distress score (day2). (B) Macroscopic appearance and 
colon length. (C) PAS-stained distal colon sections and colitis score. SM=submucosa, 
M=mucosa, infiltrating mononuclear cells, Oed=oedema (D) Systemic cytokine 
production. Data represents >3 individual experiments (n=4-10 mice) and *=p<0.05, 
**=p<0.01 and ***=p<0.001 BALB/c oxa vs. BALB/c etoh-only control mice and 
#
=p<0.05 and 
##
=p<0.01 BALB/c oxa vs. IL-4/IL-13
-/-
 oxa.  
 
Supplementary Figure 2 
IL-13 mediates oxazolone-induced colitis in BALB/c mice 
(A) Body weight (day3) and distress score (day2). (B) Macroscopic appearance and 
colon length. Data represents 2 individual experiments (n=7-10 mice) and *=p<0.05, 
**=p<0.01 and ***=p<0.001 BALB/c oxa vs. IL-13
-/-
 oxa.  
 
SUPPLEMENTARY METHODS 
Mice 
Male BALB/c mice (6-8 weeks old) and IL-4
-/-
, IL-13
-/-
, IL-4Rα-/- and IL-13 transgenic 
[IL-13
trans
] mice on a BALB/c background were used in the experiments, [1-5]. 
Furthermore, IL-4
-/-
, IL-13
-/-
, IL-4Rα-/- and IL-13trans mice were inter-crossed to generate 
IL-4/IL-13, IL-4Rα/IL-4, IL-4Rα/IL-13 double-deficient and IL-4Rα-/-/IL-13trans strains. 
All mice were housed in specific pathogen-free conditions at the University of Cape 
Town, South Africa and experiments were approved by the University’s Animal Ethics 
Committee. 
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Induction of colitis by haptenating agent oxazolone 
Oxazolone-mediated colitis was induced in BALB/c mice by modifying previously 
described methods, [6]. Anesthetized mice were sensitized on the shaved abdomen
 
by 
application of 3% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one;
 
Sigma-
Aldrich) in 100% ethanol (150µl)
 
followed 7 days later by intra-rectal administration of 
1% oxazolone
 
in 50% ethanol (150µl). Control mice were sensitized and challenged with 
ethanol only for all groups. Mice were weighed and monitored daily and killed 3 days 
post-challenge for immunopathological analyses or 6 days post-challenge for survival 
studies.  
Disease activity index 
Oxazolone treated BALB/c mice develop rapid-onset colitis marked by weight loss and 
distress score. Disease progression was determined as previously described, [6]. Briefly, 
weight loss was measured as a percentage of starting weight and distress was scored at 
day 2 post-challenge. Colon length was measured from the anus to the caecum and 
recorded as an indication of inflammation.  
Histological assessment of colitis 
Colon sections taken 1 cm from the anus were processed as previously described and 
stained with haematoxylin and eosin (H&E) for inflammatory cells or Periodic acid-
Schiff reagent (PAS) for mucus producing goblet cells. Semi-quantitative 
histopathological grading of oxazolone-induced colitis was determined as previously 
described, [6]. Mice were graded on 5 criteria, 1) presence of mononuclear cells, 2) 
reduced goblet cells, 3) epithelial injury, 4) granulocyte infiltration and 5) oedema. Each 
criteria were scored from 0-3 and the total score was added resulting in a total additive 
score of between 0 (no colitis) and 15 (maximal colitis activity). Histology sections were 
processed and stained by the Department of Surgery, Groote Schuur Hospital. 
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IL-13 production by mesenteric lymph nodes 
Individual mesenteric lymph nodes were collected from oxazolone treated mice 
respectively in complete Iscove’s Modified Dulbeccos Medium (IMDM) supplemented 
with; 10% FCS (Gibco Life Technologies), penicillin, streptomycin, 1mM sodium 
pyruvate, 50μM B2-ME (Sigma) and NEAA (Invitrogen). Single cell suspensions were 
obtained by pressing lymph nodes through a 70µm cell strainer (Falcon) and 
centrifugation at 1200rpm for 5min at 4
o
C in a 15ml tube. The pelleted cells were 
depleted of red blood cells by hypotonic lysis in Red Cell Lysis Buffer and the 
centrifugation step was repeated. Cells were resuspended in 2ml complete IMDM and 
stained with Trypan Blue (Sigma-Aldrich) to count viable cells in a haemocytometer. 
Cells were diluted to 1x10
6 
cells/ml and cultured in a 96-well plate in complete IMDM 
with anti-CD3 (clone: 145-2C11, 10μg/ml) for 48h at 37°C and 5% CO2. Supernatants 
were collected and stored at -80°C.  
Cytokine ELISA 
Sandwich ELISAs were performed to determine cytokine levels in cell supernatants. 
Maxisorp microtitre plates (Nunc) were coated with purified anti-IL-13 (clone: 38213, 
1μg/ml, BD Pharmingen), diluted in phosphate buffered saline (PBS, pH 9.5) and 
incubated overnight at 4°C. Plates were blocked with milk powder in PBS for 3h at 37°C 
and serially diluted standards, purified recombinant IL-13 (BD Pharmingen) was added. 
Cell supernatants were added, diluted in ELISA dilution buffer containing bovine serum 
albumin in PBS and incubated overnight at 4°C. Biotinylated anti-mouse secondary 
antibody for IL-13 (goat anti-mouse, 0.5μg/ml, BD Pharmingen) was added for 3h at 
37°C followed by HRP labelled streptavidin. Subsequently, plates were incubated with 
TMB Peroxidase Substrate (KPL), the colour reaction stopped with 2M H2SO4 and 
absorption measured at 450nm. ELISA wash buffer was used to wash plates 4x between 
each step. 
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Statistical analysis 
Values are given as mean ± SEM, and significant differences were determined using 
unpaired two-tailed students t test or one-way ANOVA using a Bonferroni post-test 
(GraphPad Prism). Values of p <0.05 were considered significant. 
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